Welcome to our dedicated page for Io Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on Io Biotech stock.
IO Biotech Inc. (IOBT) is a clinical-stage biopharmaceutical leader developing T-win platform-based cancer immunotherapies. This dedicated news hub provides investors and researchers with verified updates on clinical trial progress, regulatory milestones, and strategic partnerships.
Access real-time announcements about IO Biotech's innovative pipeline targeting immune inhibitory pathways, including IDO and PD-L1-focused therapies. Our curated collection features earnings reports, research publications, and corporate developments directly from company filings and authorized sources.
Key updates include phase trial results, FDA communications, intellectual property advancements, and executive team announcements. Bookmark this page for streamlined tracking of IO Biotech's progress in advancing novel cancer treatments through methodical clinical evaluation.
IO Biotech announced significant progress in its clinical trials and financial results for 2022. The company expects to enroll 75% of patients in its Phase 3 trial (IOB-013/KN-D18) for advanced melanoma by mid-2023, with full enrollment anticipated by year-end. An interim analysis could lead to a Biologics License Application for accelerated approval in the US. The Phase 2 basket study (IOB-022/KN-D38) continues to recruit patients, with data expected soon. Financially, IO Biotech reported a net loss of $71.5 million for 2022 and ended the year with $142.6 million in cash, expected to last through Q3 2024.
FAQ
What is the current stock price of Io Biotech (IOBT)?
What is the market cap of Io Biotech (IOBT)?
